Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KK-LC-1 TCR-T Cells for KK-LC-1 Positive Cancers
NCT05483491Phase 1Recruiting
- Sponsor
- Christian Hinrichs
- Start
- Sep 2022
- Primary completion
- Sep 2028
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KK-LC-1 TCR-T cells in gastric cancer (GC), breast cancer, Cervical Cancer (CC) and 1 more, sponsored by Christian Hinrichs. Primary endpoint: Maximum Tolerated Dose at 30 days. Started Sep 2022; status: recruiting.
02
Drugs
KK-LC-1 TCR-T cells
03
Conditions
gastric cancer (GC)breast cancerCervical Cancer (CC)lung cancer
Beyond the preview
Go deeper on NCT05483491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05483491.